APUI passes 100th patient dose milestone
On November 8, 2022, a patient in a clinical trial led by the ICO received a dose of Cu-ATSM produced that day at Arronax. He/she is the 101st patient to (…)
End of Ipsen clinical trial at 177lu-OPS201
Launched in November 2018 in Nantes, France, the phase 1-2 study evaluating the safety, tolerability and efficacy of 177lu-OPS201 in patients with somatostatin receptor-positive neuroendocrine tumors is nearing completion. The (…)
A COST Action dedicated to the development of astatine therapy
Resulting from a common will of the CRCINA, Arronax and the University hospital of Nantes, the project submitted by Jean-François Gestin to set up an international clinical network in Europe (…)
More than 120 participants in NTHS 2020
The 4th edition of the Nuclear Technologies for Health Symposium (NTHS) was held in Nantes on 13 and 14 February, organised by LabEx IRON in partnership with SIRIC ILIAD and (…)
A medical first in Nantes!
On 23 May 2019, a patient treated at the Institut de Cancérologie de l’Ouest (ICO) for a tumor of the rectum received a dose of 64Cu-ATSM for an imagery examination. This medical (…)